← Leaderboards
Rhea N Coler
Access To Advanced Health Institute
$15,369,963
Attributed
$20,824,718
Total exposure
12
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.7M · FY2007–25$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$25,060,760 · 13
By mechanism
R01$9,481,501 · 3
U01$6,205,726 · 1
P30$4,412,613 · 2
N01$2,219,451 · 1
R21$1,945,769 · 4
R43$600,000 · 1
Top collaborators
- Susan L. Baldwin10 shared
- Chetan Seshadri5 shared
- David R Sherman5 shared
- Sasha E. Larsen4 shared
Most similar at Access To Advanced Health Institute
Same institution · by research overlap
- Neal Scott Van Hoeven$447,374
Others in their field
Top investigators on “Immune Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$680,290,567
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,695,345
- Barton F Haynes · Duke University$456,664,915
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$309,708,725
- Peter B. Gilbert · Fred Hutchinson Cancer Center$192,329,665
Research focus
Immune ResponseMycobacterium TuberculosisDesignTuberculosisLeadInfectionPreventVaccinesFundingVaccine CandidateAdjuvantTuberculosis VaccinesPre-ClinicalAnimal ModelIn VitroResponseIn VivoMouse ModelAntigensUniversitiesDrug ResistanceCaviaBaseResearch Institute
Grant awards (30)
Seattle Tuberculosis Research Advancement Center$1,037,189
P30 · FY2025 · AI
Immunotherapeutic approach for the prevention of secondary infection with drug-resistant TB$978,349
R01 · FY2025 · AI · contact PI
Targeted vaccines against pulmonary NTM infections in vulnerable populations$950,092
R01 · FY2025 · AI · contact PI
Core-004$176,571
P30 · FY2025 · AI
Cross development of surrogate efficacy mycobacterial growth inhibition assay endpoint for the translational guinea pig model$97,850
R03 · FY2025 · AI · contact PI
Seattle Tuberculosis Research Advancement Center$1,037,189
P30 · FY2024 · AI
Immunotherapeutic approach for the prevention of secondary infection with drug-resistant TB$978,338
R01 · FY2024 · AI · contact PI
Cross development of surrogate efficacy mycobacterial growth inhibition assay endpoint for the translational guinea pig model$97,850
R03 · FY2024 · AI · contact PI
Seattle Tuberculosis Research Advancement Center$1,043,145
P30 · FY2023 · AI
Seattle Tuberculosis Research Advancement Center$1,118,519
P30 · FY2022 · AI
Advancing mycobacteriophage aerosol for prevention of pulmonary infections$235,625
R21 · FY2022 · AI · contact PI
Advancing mycobacteriophage aerosol for prevention of pulmonary infections$267,608
R21 · FY2021 · AI · contact PI
Immunotherapy to prevent drug-resistant tuberculosis$1,804,739
R01 · FY2020 · AI · contact PI
Vaccine-based immunotherapy as an adjunct to drug treatment against NTM$449,268
R21 · FY2020 · AI · contact PI
Immunotherapy to prevent drug-resistant tuberculosis$802,216
R01 · FY2019 · AI · contact PI
Vaccine-based immunotherapy as an adjunct to drug treatment against NTM$44,381
R21 · FY2019 · AI · contact PI
Immunotherapy to prevent drug-resistant tuberculosis$1,337,935
R01 · FY2018 · AI · contact PI
Immunotherapy to prevent drug-resistant tuberculosis$1,314,028
R01 · FY2017 · AI · contact PI
Identification of ID93+GLA-SE biomarkers for prevention of recurrent TB$133,950
R21 · FY2017 · AI · contact PI
Immunotherapy to prevent drug-resistant tuberculosis$1,315,804
R01 · FY2016 · AI · contact PI
Identification of ID93+GLA-SE biomarkers for prevention of recurrent TB$357,200
R21 · FY2016 · AI · contact PI
Immuno-Chemotherapy to Shorten TB Treatment$300,000
R43 · FY2015 · AI · contact PI
Immuno-Chemotherapy to Shorten TB Treatment$300,000
R43 · FY2014 · AI · contact PI
Development and Manufacture of Adjuvants for Vaccines Targeting MDR Tuberculosis$1,717,013
U01 · FY2011 · AI · contact PI
Development and Manufacture of Adjuvants for Vaccines Targeting MDR Tuberculosis$2,017,824
U01 · FY2010 · AI · contact PI
Adjuvant Development Program$2,219,451
N01 · FY2009 · AI · contact PI
Development and Manufacture of Adjuvants for Vaccines Targeting MDR Tuberculosis$1,491,583
U01 · FY2009 · AI · contact PI
Development and Manufacture of Adjuvants for Vaccines Targeting MDR Tuberculosis$979,306
U01 · FY2008 · AI · contact PI
Characterization of a vaccine against Chlamydia trachomatis$205,887
R21 · FY2008 · AI · contact PI
Characterization of a vaccine against Chlamydia trachomatis$251,850
R21 · FY2007 · AI · contact PI